Fortunately, recently completed cardiovascular and kidney outcomes trials have identified agents from the sodium–glucose co-transporter-2 (SGLT2) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 RA) classes as having important benefits on cardiovascular, kidney and HF outcomes in patients with T2D. This evidence concerns the gene GCG and type 2 diabetes mellitus.